Overview of prostate cancer
... • Highly selected patients with very high-risk localised Prostate Cancer (cT3b-T4 N0 or any T N1) in the context of multimodality treatment. ...
... • Highly selected patients with very high-risk localised Prostate Cancer (cT3b-T4 N0 or any T N1) in the context of multimodality treatment. ...
what we`ve learnt about prostate cancer in 2013 – ask a urologist!
... 1. A simple PSA blood test in your 40s can save your life and may reduce the number of tests you need in the future. A new study showed a PSA (prostate-specific antigen) test at age 45 can be used to predict a man’s long-term risk of developing an aggressive prostate cancer. The study followed up mo ...
... 1. A simple PSA blood test in your 40s can save your life and may reduce the number of tests you need in the future. A new study showed a PSA (prostate-specific antigen) test at age 45 can be used to predict a man’s long-term risk of developing an aggressive prostate cancer. The study followed up mo ...
Carcinoma of the prostate Carcinoma of the prostate is the
... protection from subsequent carcinoma. Types of prostate cancer • Microscopic latent cancer found on autopsy or at cystoprostatectomy •Tumours found incidentally during TURP (ha and Tlb); or following screening by PSA measurement — T1c •Early, localised prostate cancer (T2) • Advanced local prostate ...
... protection from subsequent carcinoma. Types of prostate cancer • Microscopic latent cancer found on autopsy or at cystoprostatectomy •Tumours found incidentally during TURP (ha and Tlb); or following screening by PSA measurement — T1c •Early, localised prostate cancer (T2) • Advanced local prostate ...
Prostate cancer (hormone-refractory) - docetaxel: Final scope
... new cases diagnosed in 2000. It is also the second most common cause of male cancer mortality, with 9940 deaths in 2002. The number of diagnoses has been increasing in recent years, but it is thought that this is due to greater monitoring of prostate specific antigen (PSA) levels in the blood, which ...
... new cases diagnosed in 2000. It is also the second most common cause of male cancer mortality, with 9940 deaths in 2002. The number of diagnoses has been increasing in recent years, but it is thought that this is due to greater monitoring of prostate specific antigen (PSA) levels in the blood, which ...
Early Detection of Prostate Cancer
... The risk of prostate cancer increases with age, especially after the age of 50.7 Men who have a family history of prostate cancer are more likely to develop prostate cancer.8 American evidence suggests that men of African heritage are at higher risk of prostate cancer.9 Physicians are encouraged to ...
... The risk of prostate cancer increases with age, especially after the age of 50.7 Men who have a family history of prostate cancer are more likely to develop prostate cancer.8 American evidence suggests that men of African heritage are at higher risk of prostate cancer.9 Physicians are encouraged to ...
Treatment of castration-resistant prostate cancer
... blood (intravenous, IV) every 4 weeks for a total of 6 treatments • Radium-223 goes to where the cancer has spread in the bone; it gives off radiation in the areas where the cancer is causing damage • Radium-223 therapy can improve patient survival and can also delay and reduce t ...
... blood (intravenous, IV) every 4 weeks for a total of 6 treatments • Radium-223 goes to where the cancer has spread in the bone; it gives off radiation in the areas where the cancer is causing damage • Radium-223 therapy can improve patient survival and can also delay and reduce t ...
Use of Advanced Treatment Technologies Among Men at
... Surveillance, Epidemiology, and End Results region. Use of advanced treatment technologies significantly increased among prostate cancer patients with low-risk disease, high risk of noncancer mortality, and both low-risk disease and high risk of noncancer mortality (P < .001 for trend). Conversely, ...
... Surveillance, Epidemiology, and End Results region. Use of advanced treatment technologies significantly increased among prostate cancer patients with low-risk disease, high risk of noncancer mortality, and both low-risk disease and high risk of noncancer mortality (P < .001 for trend). Conversely, ...
What is the prostate gland?
... If you are concerned about prostate cancer would you rather know you have cancer, or not know? If your PSA was normal would you be reassured? If you are found to have a slow growing prostate cancer and do not need to have to have treatment would you rather know you have cancer, or not know? If you h ...
... If you are concerned about prostate cancer would you rather know you have cancer, or not know? If your PSA was normal would you be reassured? If you are found to have a slow growing prostate cancer and do not need to have to have treatment would you rather know you have cancer, or not know? If you h ...
Optimal use of prostate specific antigen for prostate cancer screening
... There is strong evidence from previous reports that screening men for PCa in the PSA era should be stopped earlier than current guidelines would suggest. According to a population-based study from the pre-PSA era by Albertsen et al. 20, a significant number of PCa identified today (in the PSA era) w ...
... There is strong evidence from previous reports that screening men for PCa in the PSA era should be stopped earlier than current guidelines would suggest. According to a population-based study from the pre-PSA era by Albertsen et al. 20, a significant number of PCa identified today (in the PSA era) w ...
2ww Urology Outpatients
... With a hard, irregular prostate typical of a prostate carcinoma. Prostate-specific antigen (PSA) should be measured and the result should accompany the referral. (An urgent referral is not needed if the prostate is simply enlarged and the PSA is in the age-specific reference range). With a norma ...
... With a hard, irregular prostate typical of a prostate carcinoma. Prostate-specific antigen (PSA) should be measured and the result should accompany the referral. (An urgent referral is not needed if the prostate is simply enlarged and the PSA is in the age-specific reference range). With a norma ...
Immunotherapy and gene therapy in
... (metastasized) (mHRPC), showing an increase of the lifespan (versus placebo) of approximately 4 months (on average from 21 to 25 months) in all three phases of clinical testing. Both the principle and the course of treatment consist of three steps [5,6]: Extracting a population of lymphocytes, mai ...
... (metastasized) (mHRPC), showing an increase of the lifespan (versus placebo) of approximately 4 months (on average from 21 to 25 months) in all three phases of clinical testing. Both the principle and the course of treatment consist of three steps [5,6]: Extracting a population of lymphocytes, mai ...
Screening for Prostate Cancer - New England Journal of Medicine
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
Screening for Prostate Cancer Recommend PSA Screening
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
Screening for Prostate Cancer Recommend PSA Screening
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
... Observation Trial (PIVOT),6 active surveillance could be considered. If intermediate or high-risk prostate cancer is diagnosed (PSA level ≥10, Gleason score ≥7, or disease stage ≥T2b), given the potential survival benefit with treatment versus observation in PIVOT,6 the patient should be counseled r ...
(HRPC): Only Chemotherapy?
... showed an inhibitory effect on prostate cancer bone metastases by blocking proteolytic activity of the matrix, cell adhesion, and possibly cancer cell growth [9]. Multicentric randomised trials of HRPC with bone metastases showed a significant reduction in skeletal-related events using zoledronic ac ...
... showed an inhibitory effect on prostate cancer bone metastases by blocking proteolytic activity of the matrix, cell adhesion, and possibly cancer cell growth [9]. Multicentric randomised trials of HRPC with bone metastases showed a significant reduction in skeletal-related events using zoledronic ac ...
PDF - Canadian Task Force on Preventive Health Care
... • In many cases prostate cancer does not, and will not, pose a threat to a man’s life. ISN’T IT BETTER TO GET SCREENED THAN TO DO NOTHING? • Screening with the PSA often leads to further testing, which carries with it its own serious risks and problems. • For example, a biopsy involves a number of p ...
... • In many cases prostate cancer does not, and will not, pose a threat to a man’s life. ISN’T IT BETTER TO GET SCREENED THAN TO DO NOTHING? • Screening with the PSA often leads to further testing, which carries with it its own serious risks and problems. • For example, a biopsy involves a number of p ...
Prostate Cancer Information and Support Resources
... It is now in a newly updated edition. The Canadian Guide to Prostate Cancer. Jamnicky, Leah and Nam, Robert. 2nd edition. Mississauga, ON: John Wiley & Sons Canada, 2013. This book provides detailed information about all prostate cancer treatments, including the benefits and disadvantages of each tr ...
... It is now in a newly updated edition. The Canadian Guide to Prostate Cancer. Jamnicky, Leah and Nam, Robert. 2nd edition. Mississauga, ON: John Wiley & Sons Canada, 2013. This book provides detailed information about all prostate cancer treatments, including the benefits and disadvantages of each tr ...
